Literature DB >> 21178652

Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity.

Ralph Schneider1, Jens Waldmann, Zaher Swaid, Annette Ramaswamy, Volker Fendrich, Detlef K Bartsch, Katja Schlosser.   

Abstract

OBJECTIVE: Pancreatic endocrine tumors (PETs) are characterized by the presence of hormone syndromes. Reports focusing on calcitonin-secreting PET (CTsPETs) are very rare. This study aimed to define a CTsPET-associated syndrome in regard to chemical, anatomical, and developmental aspects.
METHODS: A computerized MEDLINE search was conducted under the search items: "pancreatic endocrine tumor," "calcitonin," "neuroendocrine pancreatic tumor," and "pancreas." Results of clinical, histopathological, immunohistochemical, and biochemical assessments of all patients identified with CTsPET were registered and statistically analyzed.
RESULTS: Thirty-seven patients with CTsPET were identified. Mean serum calcitonin was elevated to the 89.2-fold of the upper reference value. Main symptoms were watery diarrhea (51.4%) and abdominal pain (35.1%). Most patients (59.5%) presented with metastatic spread at the time of diagnosis. Of all patients, 66.7% were alive after a mean follow-up of 28.9 months. Survival was higher in patients who underwent more aggressive surgical therapies independent from tumor sizes and in those with no metastases at the time of diagnosis.
CONCLUSIONS: High calcitonin levels should always raise suspicion of medullary thyroid carcinomas. However, when thyroid examination remains without pathological findings, a CTsPET should be excluded. An aggressive surgical approach even in cases with large primary tumor sizes may lead to a longer survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21178652     DOI: 10.1097/MPA.0b013e3182015f5d

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  9 in total

1.  The calcitonin levels can sometimes mislead parathyroid surgeons in patients with chronic kidney disease and renal hyperparathyroidism: report of a case.

Authors:  Ralph Schneider; Johanna E Schaumburg; Detlef K Bartsch; Katja Schlosser
Journal:  Surg Today       Date:  2013-04       Impact factor: 2.549

Review 2.  Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.

Authors:  Silvia Uccella; Annika Blank; Roberta Maragliano; Fausto Sessa; Aurel Perren; Stefano La Rosa
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

Review 3.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

Review 4.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

5.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 6.  Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature.

Authors:  Tiziana Feola; Giulia Puliani; Franz Sesti; Roberta Modica; Marco Biffoni; Cira Di Gioia; Raffaella Carletti; Emanuela Anastasi; Valentina Di Vito; Roberta Centello; Andrea Lenzi; Andrea M Isidori; Antongiulio Faggiano; Elisa Giannetta
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-16       Impact factor: 5.555

7.  Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms.

Authors:  Kosmas Daskalakis; Eleftherios Chatzelis; Marina Tsoli; Nektaria Papadopoulou-Marketou; Georgios K Dimitriadis; Apostolos V Tsolakis; Gregory Kaltsas
Journal:  Endocrine       Date:  2018-10-02       Impact factor: 3.633

8.  Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis.

Authors:  Andrew T Magis; Noa Rappaport; Matthew P Conomos; Gilbert S Omenn; Jennifer C Lovejoy; Leroy Hood; Nathan D Price
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

9.  Extrathyroidal Calcitonin Secreting Tumors: Pancreatic Neuroendocrine Tumors in Patients With Multinodular Goiter: Two Case Reports.

Authors:  Elisa Giannetta; Daniele Gianfrilli; Carlotta Pozza; Rosa Lauretta; Chiara Graziadio; Emilia Sbardella; Alberto Baroli; Roberto Caronna; Piero Chirletti; Andrea Lenzi; Andrea M Isidori
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.